IMRX Stock Overview
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immuneering Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.43 |
| 52 Week High | US$11.92 |
| 52 Week Low | US$1.40 |
| Beta | -0.89 |
| 1 Month Change | -40.17% |
| 3 Month Change | -76.79% |
| 1 Year Change | -86.51% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.87% |
Recent News & Updates
Recent updates
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Mar 19Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Jan 06
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Aug 17Immuneering wins FDA nod to study lead asset in solid tumors
Sep 30Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
Sep 02Immuneering initiated a Buy by Chardan, PT set to $18
Jul 08Shareholder Returns
| IMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.2% | 0.4% | 1.0% |
| 1Y | -86.5% | 0.9% | 21.9% |
Return vs Industry: IMRX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: IMRX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| IMRX volatility | |
|---|---|
| IMRX Average Weekly Movement | 22.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMRX's share price has been volatile over the past 3 months.
Volatility Over Time: IMRX's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 68 | Ben Zeskind | immuneering.com |
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation Fundamentals Summary
| IMRX fundamental statistics | |
|---|---|
| Market cap | US$42.40m |
| Earnings (TTM) | -US$53.47m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs IMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$53.47m |
| Earnings | -US$53.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMRX perform over the long term?
See historical performance and comparison